Filing Flows › Aclaris Therapeutics (ACRS) › Q3 2026 › vs Q3 2025
Aclaris Therapeutics (ACRS) Q3 2026 vs Q3 2025 (year over year)
Aclaris Therapeutics's revenue fell $1.8M (-55%) from $3.3M in Q3 2025 to $1.5M in Q3 2026. The biggest changes: Licensing −$1.6M (-58%); Contract research −$185K (-38%).
Aclaris Therapeutics, Q3 2026: revenue $1.5M (-55% year over year), net loss $18.5M, operating cash flow −$24.1M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Licensing | $1.2M | $2.8M | −$1.6M | -58% |
| Contract research | $300K | $485K | −$185K | -38% |
| Revenue | $1.5M | $3.3M | −$1.8M | -55% |
| Other income, net | $2.8M | $2.5M | $299K | +12% |
| Net loss | $18.5M | $14.6M | $3.9M | +27% |
| Costs & expenses | $22.8M | $20.4M | $2.4M | +12% |
| Operating costs | $22.8M | $20.4M | $2.4M | +12% |
| Cost of revenue | $189K | $538K | −$349K | -65% |
| Research & development | $16.1M | $13.0M | $3.0M | +23% |
| General & admin | $6.0M | $4.9M | $1.2M | +24% |
| Other operating costs | $532K | $2.0M | −$1.5M | -74% |
| Operating cash sources | $27.2M | $13.9M | $13.3M | +96% |
| Depreciation & amortization | $100K | $110K | −$10K | -9% |
| Share-based compensation | $3.0M | $2.9M | $159K | +6% |
| Cash used in operations | $24.1M | $10.9M | $13.1M | +120% |
| Net loss absorbed | $18.5M | $14.6M | $3.9M | +27% |
| Working capital & other | $8.7M | −$712K | $9.4M | — |
Questions
How much did Aclaris Therapeutics's revenue grow year over year in Q3 2026?
Aclaris Therapeutics's revenue fell $1.8M (-55%) from $3.3M in Q3 2025 to $1.5M in Q3 2026.
What drove Aclaris Therapeutics's revenue change in Q3 2026?
Licensing −$1.6M (-58%); Contract research −$185K (-38%).